California’s state controller has sent a letter to Bristol-Myers Squibb (BMS) urging the company to “reduce the cost of drugs to California,” The Sacramento Bee reports. BMS drugs Atripla, Sustiva and Reyataz represent about 30 percent of all the HIV meds purchased in California. Two of the state’s largest retirement funds, which own millions of shares of BMS stock, also sent letters asking for lower prices. California’s AIDS Drug Assistance Program (ADAP) in particular is seeking price cuts for Reyataz.

To read the Sacramento Bee article, click here.